CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million.

On February 24, CF PHARMTECH announced that the Investigational New Drug application for its self-developed dry powder inhaler candidate drug, ICF004, has been accepted by the National Medical Products Administration. The acceptance of this application marks a significant milestone in the company's innovative drug development process and further demonstrates the transformative potential of its complex respiratory formulation and precision delivery platform.

It is understood that ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, a therapeutic area covering severe conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which pose significant threats to patient survival. Targeting the unmet needs in PF-ILD, the development rationale for ICF004 is based on addressing the clinical dilemma of balancing efficacy and tolerability. The drug aims to explore new delivery and mechanism pathways beyond existing treatments, with the goal of improving the therapeutic window and patient benefits.